RecruitingNCT06511908
HNK or placebo infusions for treatment-resistant depression
About this title
Read the official source — NCT06511908Medication studyAges 18–70United States
Understand this study
Who could participate?
Listed age limits: 18 years to 70 years.
What will I do during this study?
This randomized crossover study compares two weeks of HNK infusions with two weeks of saline placebo (an inactive comparison treatment); participants receive four infusions during each period. The order varies by group. The HNK dose may be adjusted according to response and tolerability, and study assessments include mood, thinking and physical-health checks.
- Listed locations
- BethesdaSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: November 6, 2024
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 50
- Sponsor
- National Institute of Mental Health (NIMH)
- Sponsor type
- Government agency
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT06511908
- Official title
Show the full official title
An Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Bethesda
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is National Institute of Mental Health (NIMH), a government agency.
Does this study involve medication?
Yes. The study involves medication, including (2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg) and Placebo.
Who can participate?
Listed age limits: 18 years to 70 years.
Is this study still recruiting?
The registry lists this study as recruiting.
